Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

CryptoTechFlowChinese, translatedFiled 16 h ago

Hong Kong stock market news: Goldman Sachs upgrades China H-share rating; BYD responds to acquisition rumors.

Original headline港股要闻:高盛上调中国 H 股评级,比亚迪回应收购传闻

Open the sourceReported by TechFlow, techflowpost.com, 16 November 2026, by TechFlowDaily

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Goldman Sachs upgraded Chinese H-shares to "overweight" on November 16, while BYD denied a rumored acquisition of a digital energy firm, saying the claim had no factual basis. In Hong Kong listings, radiopharmaceutical company Xiantong Pharma opened a public offering running through November 19, selling 6.561 million H-shares at HK$52–68 apiece. Genfleet Therapeutics said its GFH276 combination therapy for pancreatic cancer completed first patient dosing in both China and overseas trials. Separately, Simcere's Xianbixin sublingual tablets and InnoCare's zorifertinib were added to China's new national medical insurance drug list, and Fosun Pharma reported multiple products newly included, reclassified, or moved to routine list management. The moves matter as a signal of renewed foreign appetite for Chinese equities alongside steady biotech listing and reimbursement momentum; next watch the Xiantong offering's pricing and uptake, and how the insurance list changes feed through to drugmakers' revenue.

Muhabbit's AI wrote this summary in its own words from TechFlow's report and translated it from Chinese. It can get details wrong, so check the source.

Named in this story

Goldman Sachs (GS), BYD, Xiantong Pharmaceutical, InnoCare Pharma, Simcere Pharmaceutical, Fosun Pharma, Jinfang Pharmaceutical

A linked name opens that asset's sentiment page.